Field Safety Notices about Synchromed EL Implantable Pump

According to Swiss Agency for Therapeutic Products, this field safety notice involved a device in Switzerland that was produced by Medtronic Inc..

What is this?

Field safety notices are communications sent out by medical device manufacturers or their representatives in relation to actions that they may be taking in relation to their product that is on the market. These are mainly for health workers, but also for users. They can include recalls and alerts.

Learn more about the data here
  • Type of Event
    Field Safety Notice
  • Event ID
    Vk_20060606_03
  • Event Date Posted
    2006-06-14
  • Event Country
  • Event Source
    SATP
  • Event Source URL
  • Notes / Alerts
    The data from Switzerland is current through March 2018. All of the data comes from Swiss Agency for Therapeutic Products, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Switzerland.
  • Extra notes in the data

Device

  • Model / Serial
    8627 | Manufactured between March and July 1999: 8627-10: NGE000001R - NGE000242R; 8627-18: NGF000001R - NGF003266R; 8627L-10: NGG000001R - NGG000068R; 8627L-18: NGH000001R - NGH001780R
  • Product Classification
  • Product Description
    AIMD: Infusion pump, implantable, programmable
  • Manufacturer

Manufacturer

  • Manufacturer Parent Company (2017)
  • Manufacturer comment
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    SATP